OncoMatch/Clinical Trials/NCT07284433
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Is NCT07284433 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Allo-QuadCAR01-T for lymphoma diffuse large b-cell.
Treatment: Allo-QuadCAR01-T — This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: CAR-T within 3 months of screening, or ≥Grade 3 ICAHT from prior CAR-T
Prior CAR-T within 3 months of screening, or ≥Grade 3 ICAHT from prior CAR-T
Cannot have received: autologous stem cell transplant
Exception: within 3 months
Autologous stem cell transplant within 3 months
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: solid organ transplant
Prior solid organ transplant
Cannot have received: dual CD19/CD20 CAR-T
Prior therapy with dual CD19/CD20 CAR-T
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify